Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
Appointed director
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 8-K Quarterly results
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates"
07/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering"
07/11/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/11/2023 8-K Quarterly results
07/10/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/10/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ARTICLE I"
07/10/2023 8-K Quarterly results
06/16/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "OPEN MARKET SALE AGREEMENT SM June 16, 2023",
"Re: Iovance Biotherapeutics, Inc. Registration Statement on Form S-3ASR"
06/16/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/16/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
06/12/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/12/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/06/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/02/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "CONSENT OF INDEPENDENT AUDITORS",
"Index to Combined Carve-out Financial Statements Report of Independent Auditors ...................................................................................................... 2 Combined Statement of Profit or Loss and Other Comprehensive Income..................................... 4 Combined Statement of Financial Position...................................................................................... 5 Combined Statement of Changes in Parent Company Net Investment ........................................... 6 Combined Statement of Cash flows ................................................................................................ 7 Notes to the Combined carve-out financial statements…………………………&#x202...",
"2 Index to Unaudited Interim Condensed Combined Carve-out Financial Statements Unaudited Interim Condensed Combined Statement of Profit or Loss and Other Comprehensive Income 3 Unaudited Interim Condensed Combined Statement of Financial Position ....................................... 4 Unaudited Interim Condensed Combined Statement of Changes in Parent Company Net Investment 5 Unaudited Interim Condensed Combined Statement of Cash flows .................................................. 6",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS"
05/18/2023 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits  Interactive Data
05/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates"
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/24/2023 8-K Quarterly results
04/19/2023 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates"
02/14/2023 SC 13G/A PERCEPTIVE ADVISORS LLC reports a 6.3% stake in Iovance Biotherapeutics, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 9.2% stake in Iovance Biotherapeutics Inc.
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC 13G BlackRock Inc. reports a 7.7% stake in IOVANCE BIOTHERAPEUTICS, INC
02/02/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy